The competitive advantage for businesses in the life sciences industry lies in their intellectual property. As such, chief IP counsel operating in this realm are charged with the tough job of protecting their company’s IP from infringement, cyber threats, and other risks. These executives are also increasingly expected to serve as strategic partners to the business—identifying opportunities and leveraging available resources to extract more value from the IP portfolio.
Consero’s 2017 Life Sciences IP Report was developed in partnership with Sterne, Kessler, Goldstein & Fox and in connection with its 2017 events for IP executives in the life sciences. Respondents included heads of IP from corporations involved with medical devices, pharmaceuticals, and biotechnology in the U.S. and Europe. The 15-question survey yielded responses from 57 participants.